[Liver transplantation for hepatitis C virus cirrhosis--present status and future prospects].
Sugawara
Yasuhiko
Y
Artificial Organ & Transplantation Division, Department of Surgery, Faculty of Medicine, University of Tokyo.
Makuuchi
Masatoshi
M
D000998:Antiviral Agents / Q000008:administration & dosage; D001926:Brain Death; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006085:Graft Survival; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007564:Japan / Q000453:epidemiology; D008103:Liver Cirrhosis / Q000209:etiology* / Q000628:therapy* / Q000821:virology; D016031:Liver Transplantation / Q000706:statistics & numerical data; D019520:Living Donors; D011379:Prognosis; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage; D012307:Risk Factors
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin